STOCK TITAN

BlackRock Health Sciences’ tender offer expires Nov. 18

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SC TO-I/A

Rhea-AI Filing Summary

BlackRock Health Sciences Term Trust (BMEZ) amended its tender-offer statement to add a press release announcing preliminary results of its offer, which expired November 18, 2026. The offer covered up to 5% of issued and outstanding common shares for cash at 98% of per-share net asset value.

Shares covered by offer Up to 5% Maximum portion of issued and outstanding common shares covered by the offer.
Cash price 98% of per-share net asset value Offer price per share.
Offer expiration November 18, 2026, at 5:00 p.m. Eastern time The offer expired at this time.
net asset value (NAV) financial
"net asset value (“NAV”) per Share"
Net asset value (NAV) is the per-share value of an investment fund calculated by totaling the fund’s assets, subtracting its liabilities, and dividing the remainder by the number of outstanding shares. Think of it like a price tag on each share of a collective piggy bank: investors use NAV to see what each share is worth, to compare funds, and, for many funds, it’s the price at which shares are bought or redeemed.
Issuer Tender Offer Statement regulatory
"Issuer Tender Offer Statement on Schedule TO"
An issuer tender offer statement is a formal disclosure a company provides when it offers to buy back its own shares or other securities directly from holders. It lays out the offer’s terms, how it will be paid for, why the company is doing it, and any risks or effects on shareholders, so investors can compare the proposal to keeping their holdings—much like a clear invitation that lists price, timing and consequences before you decide to sell.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What were BMEZ’s tender offer terms?

BMEZ offered to repurchase up to 5% of its issued and outstanding common shares for cash at 98% of per-share NAV. NAV was to be determined at the close of the regular trading session on the next day it was calculated after the offer expired.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 
 

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

 

SCHEDULE TO

TENDER OFFER STATEMENT

Under Section 14(d)(1) or 13(e)(1)

of the Securities Exchange Act of 1934

(Amendment No. 1)

 

 

BlackRock Health Sciences Term Trust

(Name of Subject Company (Issuer))

BlackRock Health Sciences Term Trust

(Names of Filing Person(s) (Issuer))

Common Shares of Beneficial Interest, Par Value $0.001 per share

(Title of Class of Securities)

09260E105

(CUSIP Number of Class of Securities)

John M. Perlowski

BlackRock Health Sciences Term Trust

50 Hudson Yards

New York, New York 10001

(800) 882-0052

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications on Behalf of Filing Person(s))

 

 

Copies to:

 

Margery K. Neale, Esq.  
Elliot J. Gluck, Esq.   Janey Ahn, Esq.
Willkie Farr & Gallagher LLP   BlackRock Advisors, LLC
787 Seventh Avenue   50 Hudson Yards
New York, New York 10019   New York, New York 10001

 

 

October 16, 2026

(Date Tender Offer First Published, Sent or Given to Security Holders)

 

 

 

☐

Check the box if the filing relates solely to preliminary communications made before the commencement of a tender offer.

Check the appropriate boxes below to designate any transactions to which this statement relates:

 

  ☐

third-party tender offer subject to Rule 14d-1

  ☒

issuer tender offer subject to Rule 13e-4

  ☐

going-private transaction subject to Rule 13e-3

  ☐

amendment to Schedule 13D under Rule 13d-2

Check the following box if the filing is a final amendment reporting the results of the tender offer. ☐

 

 
 


This Amendment No. 1 (“Amendment No. 1”) amends and supplements the Issuer Tender Offer Statement on Schedule TO filed on October 16, 2026 (the “Schedule TO”) by BlackRock Health Sciences Term Trust, a Maryland statutory trust (the “Fund”), pursuant to Rule 13e-4 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), in connection with an offer by the Fund (the “Offer”) to repurchase up to 5% of its issued and outstanding common shares of beneficial interest, par value $0.001 per share (the “Shares”), in exchange for cash at a price equal to 98% of the net asset value (“NAV”) per Share determined as of the close of the regular trading session of the New York Stock Exchange, the principal market on which the Shares are traded, on the next day the NAV is calculated after the Offer expires, upon the terms and subject to the conditions set forth in the Offer to Purchase, dated October 16, 2026 (the “Offer to Purchase”), and in the related Letter of Transmittal, copies of which were previously filed as Exhibits (a)(1)(i) and (a)(1)(ii), respectively, to the Schedule TO.

This Amendment No. 1 is being filed to update Item 12 of the Schedule TO to include a press release announcing the preliminary results of the Offer, which expired on November 18, 2026, at 5:00 p.m. Eastern time. A copy of the press release is attached hereto as Exhibit (a)(5)(ii).

Except as specifically provided herein, this Amendment No. 1 does not modify any of the information previously reported in the Schedule TO, as amended, or the Letter of Transmittal.

Item 1 through Item 9 and Item 11

The information set forth in the Offer to Purchase and the related Letter of Transmittal is incorporated by reference into this Amendment No. 1 in answer to Item 1 through Item 9 and Item 11 of the Schedule TO.

Item 10. Financial Statements

(a) The audited annual financial statements of the Fund dated December 31, 2025 and the schedule of investments of the Fund dated December 31, 2025, both filed with the SEC on EDGAR on Form N-CSR on March 5, 2026, are incorporated by reference. The unaudited semi-annual financial statements of the Fund dated June 30, 2026 and the schedule of investments of the Fund dated June  30, 2026, both filed with the SEC on EDGAR on Form N-CSRS on September 3, 2026, are incorporated by reference.

(b) Not applicable.

Item 12(a). Exhibits

Item 12(a) of the Schedule TO is hereby amended and supplemented to add the following exhibit:

(a)(5)(ii) Press release issued on November 18, 2026 is filed herewith.

Item 12(c). Filing Fees

Filing Fee Exhibit

Item 13. Information Required By Schedule 13E-3

Not Applicable.

 

- 2 -


SIGNATURE

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

BlackRock Health Sciences Term Trust
By:  

/s/ John M. Perlowski

  Name: John M. Perlowski
  Title: President and Chief Executive Officer
  Dated: November 18, 2026

 

- 3 -


Exhibit Index

 

Exhibit
Number
 

Description

(a)(5)(ii)   Press release issued on November 18, 2026
  Filing Fee Exhibit

 

- 4 -

Keep reading